shr-1703
mAbexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jul 22, 2020 (NCT04480762)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06653322 | Phase 3 | Oct 31, 2024 | Hengrui Therapeutics, Inc. |
| NCT06441812 | Phase 2 | Jun 30, 2024 | Hengrui Therapeutics, Inc. |
| NCT05979051 | Phase 2/Phase 3 (Phase 3) | Nov 16, 2023 | Hengrui Therapeutics, Inc. |
| NCT05522439 | Phase 2 | Oct 30, 2022 | Hengrui Therapeutics, Inc. |
| NCT05042401 | Phase 1 | Sep 1, 2021 | Hengrui Therapeutics, Inc. |
| NCT04855591 | Phase 1 | Jun 14, 2021 | Atridia Pty Ltd., Nucleus Network Ltd |
| NCT04480762 | Phase 1 | Jul 22, 2020 | Hengrui Therapeutics, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 6 | 6 | 3 | 2020 |
| Atridia Pty Ltd. | For profit | 1 | 1 | 1 | 2021 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1